Tempest Therapeutics Inc (TPST)

Tempest Therapeutics Inc.: A Comprehensive Overview

Company Profile

History and Background:

Founded in 2015, Tempest Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients suffering from cancer and other serious diseases. The company utilizes its proprietary Lymph-Sparing Platform™ to target specific tissues and achieve superior therapeutic outcomes while minimizing systemic toxicity. Tempest Therapeutics Inc. is headquartered in New York City and has additional facilities in Massachusetts.

Core Business Areas:

Tempest Therapeutics Inc. focuses on developing two key areas:

1. Oncology: The company's lead program, TPST-1120, is a first-in-class OX40 agonist being evaluated in Phase 1/2 clinical trials for the treatment of advanced solid tumors.
2. Autoimmune and Inflammatory Diseases: Tempest Therapeutics Inc. is also exploring other potential applications of its Lymph-Sparing Platform™ in autoimmune and inflammatory diseases.

Leadership Team and Corporate Structure:

The company is led by a team of experienced professionals with extensive expertise in drug development and commercialization. The executive leadership team includes:

• CEO and President: Alexis Borisy, Ph.D.
• Chief Medical Officer: Stephen Gately, M.D.
• Chief Scientific Officer: Jonathan Pachter, Ph.D.
• Chief Financial Officer: Mark Guagliardo

Tempest Therapeutics Inc. has a Board of Directors composed of industry veterans and scientific experts.

Top Products and Market Share

Top Products:

• TPST-1120: This OX40 agonist is currently in Phase 1/2 clinical trials for the treatment of advanced solid tumors. It has demonstrated promising preclinical data, including tumor regressions in syngeneic mouse models.

Market Share:

As TPST-1120 is still in clinical development, it does not currently have a market share. However, the OX40 agonist market is estimated to reach $2.5 billion by 2028, presenting a significant opportunity for Tempest Therapeutics Inc.

Competitor Comparison:

Tempest Therapeutics Inc. faces competition from other companies developing OX40 agonists, such as:

• Pfizer: PF-04518600
• Roche: RG6234
• Bristol Myers Squibb: BMS-986207

Tempest Therapeutics Inc. differentiates itself by its Lymph-Sparing Platform™, which could offer a more favorable safety profile compared to other OX40 agonists.

Total Addressable Market

The global oncology market is estimated to be worth $175 billion in 2023 and is projected to grow at a CAGR of 9.4% to reach $275 billion by 2028. The OX40 agonist market is a subset of this, representing a significant opportunity for Tempest Therapeutics Inc.

Financial Performance

Recent Financial Statements:

• Revenue: As a clinical-stage company, Tempest Therapeutics Inc. does not currently generate significant revenue.
• Net Income: The company is currently incurring losses due to its early-stage development activities.
• Profit Margins: Not applicable at this stage.
• Earnings per Share (EPS): Not applicable at this stage.

Year-over-Year Comparison:

As the company is in its early stages, year-over-year comparisons are not meaningful at this time.

Cash Flow and Balance Sheet:

Cash and equivalents as of December 31, 2022, stood at $265.4 million, providing sufficient runway for ongoing clinical trials and operations.

Dividends and Shareholder Returns

Dividend History:

Tempest Therapeutics Inc. does not currently pay dividends as it focuses on reinvesting its resources in research and development.

Shareholder Returns:

The company's stock price has fluctuated significantly since its IPO in 2021. Investors should be aware of the inherent risk associated with investing in early-stage companies.

Growth Trajectory

Historical Growth:

As a recently public company, Tempest Therapeutics Inc. does not have a long history of growth. However, the company has made significant progress in advancing its lead program, TPST-1120, into clinical trials.

Future Growth Projections:

Analysts expect the company's stock to grow significantly as it progresses through clinical development and potentially obtains regulatory approval for its products.

Growth Drivers:

• Success of ongoing clinical trials for TPST-1120
• Expansion into new therapeutic areas
• Strategic partnerships and collaborations

Market Dynamics

Industry Trends:

The biotechnology and pharmaceutical industries are undergoing rapid technological advancements, with a growing focus on personalized medicine and targeted therapies.

Competitive Landscape:

The OX40 agonist market is becoming increasingly competitive, with several companies vying for market share. Tempest Therapeutics Inc. needs to differentiate itself through its innovative platform technology and promising clinical data.

Competitors

• Pfizer (PFE): Market cap $241.31 billion. Strong presence in the oncology market with established products like Ibrance and Xtandi.
• Roche (RHHBY): Market cap $286.09 billion. A leading player in the biopharmaceutical industry with a diverse product portfolio.
• Bristol Myers Squibb (BMY): Market cap $142.12 billion. Another major pharmaceutical company with a strong focus on oncology.

Potential Challenges and Opportunities

Challenges:

• Competition in the OX40 agonist market
• Regulatory hurdles and risks associated with clinical development
• Dependence on a limited number of product candidates

Opportunities:

• Success of ongoing clinical trials for TPST-1120 could lead to significant growth
• Expansion into new therapeutic areas
• Strategic partnerships for co-development or commercialization of products

Recent Acquisitions (last 3 years):

Tempest Therapeutics Inc. has not acquired any companies in the past three years.

AI-Based Fundamental Rating

Rating: 7/10

Justification:

Tempest Therapeutics Inc. is a promising company with a strong focus on innovation and a differentiated technology platform. However, it faces challenges in a competitive market and is still in the early stages of development. The assigned rating reflects the company's potential and its current stage of development.

Sources and Disclaimers

Sources:

• Tempest Therapeutics Inc. investor relations website
• Securities and Exchange Commission filings
• Market research reports

Disclaimers:

• This analysis is for informational purposes only and should not be considered investment advice.
• Investors should conduct their own due diligence before making any investment decisions.